TOP TEN perturbations for 1553537_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1553537_at
Selected probe(set): 237507_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553537_at (237507_at) across 6672 perturbations tested by GENEVESTIGATOR:

wound healing study 2 (ex vivo; DMSO) / normal skin tissue (ex vivo)

Relative Expression (log2-ratio):-2.8186464
Number of Samples:3 / 3
Experimental wound healing study 2 (ex vivo; DMSO)
Ex vivo skin samples obtained from healthy donors following reduction surgery of abdomen, and incubated in culture medium containing DMSO for 4 days. To make sure that mainly epidermis was present in the samples, as much dermal tissue as possible was removed by dissection. Skin was sliced into 1x10 mm slices and incubated in keratinocyte medium for four days with 1:1000 fold dilution of DMSO. The cultivation was performed in serum-free keratinocyte medium supplemented with transferrin, hEGF (0.15 ng/mL), 0.5 mg/mL hydrocortisone, gentamicin, amphotericin B, and epinephrine but without insulin.
Control normal skin tissue (ex vivo)
Normal skin samples obtained from healthy donors following reduction surgery of abdomen. To make sure that mainly epidermis was present in the samples, as much dermal tissue as possible was removed by dissection.

diphenylcyclopropenone study 1 (late) / diphenylcyclopropenone study 1 (early)

Relative Expression (log2-ratio):2.7825184
Number of Samples:6 / 10
Experimental diphenylcyclopropenone study 1 (late)
Skin biopsy samples of healthy volunteers exposed to diphenylcyclopropenone (diphencyprone; DPCP) for 4 to 8 months. ATC code:---
Control diphenylcyclopropenone study 1 (early)
Skin biopsy samples of healthy volunteers exposed to diphenylcyclopropenone (diphencyprone; DPCP) for 3 days. ATC code:---

alopecia areata study 1 (AU; lesional; validation) / normal skin tissue (validation)

Relative Expression (log2-ratio):-2.679615
Number of Samples:9 / 13
Experimental alopecia areata study 1 (AU; lesional; validation)
Lesional scalp skin punch biopsies obtained from patients who suffered from alopecia areata universalis (AU) assigned to validation dataset.
Control normal skin tissue (validation)
Scalp skin punch biopsies obtained from healthy donors assigned to validation dataset.

alopecia areata study 1 (AT; lesional; discovery) / normal skin tissue (discovery)

Relative Expression (log2-ratio):-2.473195
Number of Samples:6 / 23
Experimental alopecia areata study 1 (AT; lesional; discovery)
Lesional scalp skin punch biopsies obtained from patients who suffered from alopecia areata totalis (AT) assigned to discovery dataset.
Control normal skin tissue (discovery)
Scalp skin punch biopsies obtained from healthy donors assigned to discovery dataset.

psoriasis study 24 (lesional; baseline; ustekinumab; 45mg; responder) / psoriasis study 24 (lesional; baseline; ustekinumab; 45mg; non-responder)

Relative Expression (log2-ratio):2.4528198
Number of Samples:15 / 2
Experimental psoriasis study 24 (lesional; baseline; ustekinumab; 45mg; responder)
Lesional skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with 45 mg ustekinumab) and assigned as responders. Responders are patients who achieved ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Lesional skin samples were isolated from a representative psoriatic target lesion (≥ 3cm). Patients participated in a phase 3 of Psoriasis Trial ACCEPT.
Control psoriasis study 24 (lesional; baseline; ustekinumab; 45mg; non-responder)
Lesional skin punch biopsies derived from patients with moderate-to-severe psoriasis at baseline (prior to treatment with 45 mg ustekinumab) and assigned as non-responders. Non-responders are patients who did not achieve ≥75% improvement from baseline in Psoriasis Area and Severity Index (PASI75) at week 12. Lesional skin samples were isolated from a representative psoriatic target lesion (≥ 3cm). Patients participated in a phase 3 of Psoriasis Trial ACCEPT.

wound healing study 2 (ex vivo; AG1478) / normal skin tissue (ex vivo)

Relative Expression (log2-ratio):-2.19244
Number of Samples:3 / 3
Experimental wound healing study 2 (ex vivo; AG1478)
Ex vivo skin samples obtained from healthy donors following reduction surgery of abdomen, and incubated in culture medium containing AG1478 for 4 days. To make sure that mainly epidermis was present in the samples, as much dermal tissue as possible was removed by dissection. Skin was sliced into 1x10 mm slices and incubated in keratinocyte medium for four days with 10 micromolar AG1478 (dissolved in DMSO). The cultivation was performed in serum-free keratinocyte medium supplemented with transferrin, hEGF (0.15 ng/mL), 0.5 mg/mL hydrocortisone, gentamicin, amphotericin B, and epinephrine but without insulin. AG1478 is EGFR kinase inhibitor. ATC code:---
Control normal skin tissue (ex vivo)
Normal skin samples obtained from healthy donors following reduction surgery of abdomen. To make sure that mainly epidermis was present in the samples, as much dermal tissue as possible was removed by dissection.

cutaneous T-cell lymphoma study 1 (patch phase) / normal skin tissue

Relative Expression (log2-ratio):-2.186841
Number of Samples:2 / 8
Experimental cutaneous T-cell lymphoma study 1 (patch phase)
Lesional skin biopsies from patients with cutaneous T-cell lymphoma in the patch phase.
Control normal skin tissue
Skin biopsies from healthy individuals.

cutaneous T-cell lymphoma study 1 (plaque phase) / normal skin tissue

Relative Expression (log2-ratio):-2.178568
Number of Samples:7 / 8
Experimental cutaneous T-cell lymphoma study 1 (plaque phase)
Lesional skin biopsies from patients with cutaneous T-cell lymphoma in the plaque phase.
Control normal skin tissue
Skin biopsies from healthy individuals.

cutaneous T-cell lymphoma study 1 (tumor phase) / normal skin tissue

Relative Expression (log2-ratio):-2.1399088
Number of Samples:4 / 8
Experimental cutaneous T-cell lymphoma study 1 (tumor phase)
Lesional skin biopsies from patients with cutaneous T-cell lymphoma in the tumor phase (extranodal).
Control normal skin tissue
Skin biopsies from healthy individuals.

diphenylcyclopropenone study 1 (early) / placebo treated skin tissue

Relative Expression (log2-ratio):-2.1129465
Number of Samples:10 / 11
Experimental diphenylcyclopropenone study 1 (early)
Skin biopsy samples of healthy volunteers exposed to diphenylcyclopropenone (diphencyprone; DPCP) for 3 days. ATC code:---
Control placebo treated skin tissue
Skin biopsy samples of healthy volunteers exposed to placebo for 3 days.